Abstract
Finding ways to target the alternative (ALT) telomere lengthening pathway found in some cancer cells could complement telomerase inhibitors currently in clinical trials.
Original language | English (US) |
---|---|
Pages (from-to) | 1388-1390 |
Number of pages | 3 |
Journal | Science |
Volume | 336 |
Issue number | 6087 |
DOIs | |
State | Published - Jun 15 2012 |
ASJC Scopus subject areas
- General